{"url":"https://lda.senate.gov/api/v1/filings/63fdec39-bd73-4f31-be6d-d78f48d439bf/","filing_uuid":"63fdec39-bd73-4f31-be6d-d78f48d439bf","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2024,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/63fdec39-bd73-4f31-be6d-d78f48d439bf/print/","filing_document_content_type":"text/html","income":"30000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Anna Weinstein","dt_posted":"2025-01-21T21:18:21-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"613 E ST SE","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20003","registrant":{"id":401107496,"url":"https://lda.senate.gov/api/v1/registrants/401107496/","house_registrant_id":56036,"name":"GREEN MOUNTAIN STRATEGIES LLC DC","description":null,"address_1":"613 E ST SE","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20003","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ANNA WEINSTEIN","contact_telephone":"+1 202-531-1363","dt_updated":"2026-01-29T18:27:14.099314-05:00"},"client":{"id":55620,"url":"https://lda.senate.gov/api/v1/clients/55620/","client_id":55620,"name":"ALVOGEN","general_description":"Pharmaceutical company developing and manufacturing generic, brand and biosimilar products","client_government_entity":null,"client_self_select":false,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-02-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Regulatory and legislative issues related to development and procurement of pandemic influenza antivirals including Strategic National Stockpile appropriations and reauthorization of the Pandemic and All-Hazards Preparedness Act, S.2333, Pandemic and All-Hazards Preparedness and Response Act, H.R.4421, Preparing for All Hazards and Pathogens Reauthorization Act; S.2624/HR 5894, Fiscal Year 2025 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145233,"prefix":"ms","prefix_display":"MS.","first_name":"ANNA","nickname":null,"middle_name":"KATHERINE","last_name":"WEINSTEIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}